General Information of Drug (ID: DMKQYMX)

Drug Name
NSC-137546 Drug Info
Synonyms NSC-137546; NSC137546; CHEMBL591202; AC1L5Y49; AKOS008984447; 2-[(2,6-dichlorobenzoyl)amino]pentanedioic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
283188
TTD Drug ID
DMKQYMX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [1]
PMID27376512-Compound-MTC-424 DMGNRZU N. A. N. A. Patented [2]
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [2]
PMID27376512-Compound-MTC-422 DM1MVQD N. A. N. A. Patented [2]
PMID27376512-Compound-MTC-423 DM9RSDX N. A. N. A. Patented [2]
(L-)-S-adenosyl-L-homocysteine DMDUN83 Discovery agent N.A. Investigative [3]
NSC-622445 DME35CB Discovery agent N.A. Investigative [1]
NSC-622444 DMM5UT9 Discovery agent N.A. Investigative [1]
NSC-138419 DMH684Q Discovery agent N.A. Investigative [1]
NSC-319745 DMF3G06 Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Azacitidine DMTA5OE Acute myelogenous leukaemia 2A41 Approved [4]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [1]
S-110 DMXY34J Acute myeloid leukaemia 2A60 Phase 3 [5]
ASTX727 DM4HK8Z Chronic myelogenous leukaemia 2A20.0 Phase 3 [6]
PMID27376512-Compound-PG-11047 DM5K4YF N. A. N. A. Patented [2]
PMID27376512-Compound-PG-11048 DM3U7RN N. A. N. A. Patented [2]
PMID27376512-Compound-MTC-434 DM70CTE N. A. N. A. Patented [2]
PMID27376512-Compound-CROs DMBFUTL N. A. N. A. Patented [2]
(L-)-S-adenosyl-L-homocysteine DMDUN83 Discovery agent N.A. Investigative [3]
NSC-622445 DME35CB Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA [cytosine-5]-methyltransferase (DNMT) TTHVCUP NOUNIPROTAC Inhibitor [1]
DNA [cytosine-5]-methyltransferase 3B (DNMT3B) TT6VZ78 DNM3B_HUMAN Inhibitor [1]

References

1 Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
2 DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
3 Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
4 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)